Stereotactic ablative body radiotherapy (SABR) is a newer form of radiation treatment that delivers high doses to specific body sites over a shorter treatment period than conventional radiotherapy. For cancer therapy, including oligometastatic cancer, SABR is a non-invasive alternative to surgical treatment and an option for patients who are medically inoperable. However, there is a need to determine which patients should be treated with SABR to achieve the greatest benefit and how their disease should be managed. To inform decision-making on the expanded use of SABR in Canada, CADTH is undertaking a Health Technology Assessment (HTA).
As part of this HTA, a clinical review was completed regarding the effectiveness and safety of SABR, with or without standard care, for the treatment of oligometastatic cancer. This review is being regularly updated according to a living systematic review approach. CADTH is also undertaking an Environmental Scan of implementation considerations that will contribute to this HTA to further support decision-making.